Evotec receives first milestones in TargetAD collaboration
Evotec AG announced the successful achievement of the first milestones in its TargetAD collaboration with Janssen Pharmaceuticals, Inc. ("Janssen") for the identification and selection of three selected targets from the TargetADdatabase.
These target selections were achieved under the agreement between Evotec and Janssen, facilitated by the Johnson & Johnson Innovation Center in California, signed in November 2013. Under the terms of the agreement, Janssen and Evotec are collaborating to identify new drug targets for discovery of novel treatment approaches to Alzheimer's disease ('AD').
Janssen has the option to internalize selected targets and therapeutic candidates and progress them into pre-clinical and clinical development. Janssen funds target drug discovery research via a combination of defined research payments and progress-related milestones.
Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "We are delighted to see the first validation of our collaboration with Janssen. The joint project team has been very productive and we are looking forward to leveraging our innovative Alzheimer's disease approaches during the years to come."
Other news from the department business & finance
